

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal
- Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82











